An economic evaluation of two PCR-based respiratory panel assays for patients admitted to hospital with community-acquired pneumonia (CAP) in the UK, France and Spain
Abstract Background On admission to hospital, patients with community-acquired pneumonia (CAP), undergo extensive diagnostic testing. Two high-throughput laboratory-based PCR panels which return a result in 5.5 hours (h) have been developed to test for pathogens commonly associated with upper (Respi...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2023-06-01
|
| Series: | BMC Pulmonary Medicine |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s12890-023-02516-2 |
| _version_ | 1797454045493854208 |
|---|---|
| author | Lisa Miners Susie Huntington Nathaniel Lee Katy M. E. Turner Elisabeth Adams |
| author_facet | Lisa Miners Susie Huntington Nathaniel Lee Katy M. E. Turner Elisabeth Adams |
| author_sort | Lisa Miners |
| collection | DOAJ |
| description | Abstract Background On admission to hospital, patients with community-acquired pneumonia (CAP), undergo extensive diagnostic testing. Two high-throughput laboratory-based PCR panels which return a result in 5.5 hours (h) have been developed to test for pathogens commonly associated with upper (Respiratory 1 Panel) and lower (Respiratory 3 Panel) respiratory tract infections (GeneFirst, Oxford). These could replace multiple diagnostic tests currently used. Methods An online survey, completed by senior clinicians in the UK, France and Spain, was used to collect data on the diagnostic testing of immunocompetent and immunocompromised adults admitted to hospital with CAP, including the cost of diagnostics. Data were used to inform a cost-comparison model. For each country, the average cost of diagnostic testing per patient was calculated separately for immunocompetent and immunocompromised patients. The model compared three testing strategies with standard of care (SoC). In the Panel 1 strategy, the Respiratory 1 Panel was used for patients that would otherwise have tests which could be replaced by Respiratory 1 Panel, equivalent strategies for Respiratory 3 Panel and for both panels combined were assessed. Results In total, 48 surveys were completed (UK = 17; France = 15; Spain = 16). Compared with SoC, the Panel 1 + 3 strategy was most favourable, resulting in cost savings for immunocompetent and immunocompromised patients respectively, of €22.09 (£18.50) and €26.12 (£21.88) in the UK, €99.60 and €108.77 in France and €27.07 and €51.87 in Spain. Conclusion In all three countries, the use of these respiratory panels could reduce the average cost of diagnostics used for patients admitted to hospital with CAP. |
| first_indexed | 2024-03-09T15:31:36Z |
| format | Article |
| id | doaj.art-c7f4666c9a3841588b0acc12f049347b |
| institution | Directory Open Access Journal |
| issn | 1471-2466 |
| language | English |
| last_indexed | 2024-03-09T15:31:36Z |
| publishDate | 2023-06-01 |
| publisher | BMC |
| record_format | Article |
| series | BMC Pulmonary Medicine |
| spelling | doaj.art-c7f4666c9a3841588b0acc12f049347b2023-11-26T12:13:20ZengBMCBMC Pulmonary Medicine1471-24662023-06-0123111010.1186/s12890-023-02516-2An economic evaluation of two PCR-based respiratory panel assays for patients admitted to hospital with community-acquired pneumonia (CAP) in the UK, France and SpainLisa Miners0Susie Huntington1Nathaniel Lee2Katy M. E. Turner3Elisabeth Adams4Aquarius Population HealthAquarius Population HealthHospital for Tropical Diseases, University College London Hospital NHS Foundation TrustAquarius Population HealthAquarius Population HealthAbstract Background On admission to hospital, patients with community-acquired pneumonia (CAP), undergo extensive diagnostic testing. Two high-throughput laboratory-based PCR panels which return a result in 5.5 hours (h) have been developed to test for pathogens commonly associated with upper (Respiratory 1 Panel) and lower (Respiratory 3 Panel) respiratory tract infections (GeneFirst, Oxford). These could replace multiple diagnostic tests currently used. Methods An online survey, completed by senior clinicians in the UK, France and Spain, was used to collect data on the diagnostic testing of immunocompetent and immunocompromised adults admitted to hospital with CAP, including the cost of diagnostics. Data were used to inform a cost-comparison model. For each country, the average cost of diagnostic testing per patient was calculated separately for immunocompetent and immunocompromised patients. The model compared three testing strategies with standard of care (SoC). In the Panel 1 strategy, the Respiratory 1 Panel was used for patients that would otherwise have tests which could be replaced by Respiratory 1 Panel, equivalent strategies for Respiratory 3 Panel and for both panels combined were assessed. Results In total, 48 surveys were completed (UK = 17; France = 15; Spain = 16). Compared with SoC, the Panel 1 + 3 strategy was most favourable, resulting in cost savings for immunocompetent and immunocompromised patients respectively, of €22.09 (£18.50) and €26.12 (£21.88) in the UK, €99.60 and €108.77 in France and €27.07 and €51.87 in Spain. Conclusion In all three countries, the use of these respiratory panels could reduce the average cost of diagnostics used for patients admitted to hospital with CAP.https://doi.org/10.1186/s12890-023-02516-2Community-acquired pneumoniaDiagnosticsMicrobiologyCOVID-19InfluenzaLegionella |
| spellingShingle | Lisa Miners Susie Huntington Nathaniel Lee Katy M. E. Turner Elisabeth Adams An economic evaluation of two PCR-based respiratory panel assays for patients admitted to hospital with community-acquired pneumonia (CAP) in the UK, France and Spain BMC Pulmonary Medicine Community-acquired pneumonia Diagnostics Microbiology COVID-19 Influenza Legionella |
| title | An economic evaluation of two PCR-based respiratory panel assays for patients admitted to hospital with community-acquired pneumonia (CAP) in the UK, France and Spain |
| title_full | An economic evaluation of two PCR-based respiratory panel assays for patients admitted to hospital with community-acquired pneumonia (CAP) in the UK, France and Spain |
| title_fullStr | An economic evaluation of two PCR-based respiratory panel assays for patients admitted to hospital with community-acquired pneumonia (CAP) in the UK, France and Spain |
| title_full_unstemmed | An economic evaluation of two PCR-based respiratory panel assays for patients admitted to hospital with community-acquired pneumonia (CAP) in the UK, France and Spain |
| title_short | An economic evaluation of two PCR-based respiratory panel assays for patients admitted to hospital with community-acquired pneumonia (CAP) in the UK, France and Spain |
| title_sort | economic evaluation of two pcr based respiratory panel assays for patients admitted to hospital with community acquired pneumonia cap in the uk france and spain |
| topic | Community-acquired pneumonia Diagnostics Microbiology COVID-19 Influenza Legionella |
| url | https://doi.org/10.1186/s12890-023-02516-2 |
| work_keys_str_mv | AT lisaminers aneconomicevaluationoftwopcrbasedrespiratorypanelassaysforpatientsadmittedtohospitalwithcommunityacquiredpneumoniacapintheukfranceandspain AT susiehuntington aneconomicevaluationoftwopcrbasedrespiratorypanelassaysforpatientsadmittedtohospitalwithcommunityacquiredpneumoniacapintheukfranceandspain AT nathaniellee aneconomicevaluationoftwopcrbasedrespiratorypanelassaysforpatientsadmittedtohospitalwithcommunityacquiredpneumoniacapintheukfranceandspain AT katymeturner aneconomicevaluationoftwopcrbasedrespiratorypanelassaysforpatientsadmittedtohospitalwithcommunityacquiredpneumoniacapintheukfranceandspain AT elisabethadams aneconomicevaluationoftwopcrbasedrespiratorypanelassaysforpatientsadmittedtohospitalwithcommunityacquiredpneumoniacapintheukfranceandspain AT lisaminers economicevaluationoftwopcrbasedrespiratorypanelassaysforpatientsadmittedtohospitalwithcommunityacquiredpneumoniacapintheukfranceandspain AT susiehuntington economicevaluationoftwopcrbasedrespiratorypanelassaysforpatientsadmittedtohospitalwithcommunityacquiredpneumoniacapintheukfranceandspain AT nathaniellee economicevaluationoftwopcrbasedrespiratorypanelassaysforpatientsadmittedtohospitalwithcommunityacquiredpneumoniacapintheukfranceandspain AT katymeturner economicevaluationoftwopcrbasedrespiratorypanelassaysforpatientsadmittedtohospitalwithcommunityacquiredpneumoniacapintheukfranceandspain AT elisabethadams economicevaluationoftwopcrbasedrespiratorypanelassaysforpatientsadmittedtohospitalwithcommunityacquiredpneumoniacapintheukfranceandspain |